Sign up Australia
Proactive Investors - Run By Investors For Investors

Holista CollTech to file patent for world’s first all-natural low-GI sugar

Holista CollTech (ASX:HCT) has collaborated with 2017 Nobel Prize nominee Daryl Thompson to file a patent for the world’s first low glycemic index (GI) sugar made out of all-natural ingredients.
Holista CollTech to file patent for world’s first all-natural low-GI sugar
Holista’s shares were last trading at $0.135, up 28.6% intra-day.

Daryl Thompson is an emerging thought leader in carbohydrate chemistry who was nominated for the 2015 and 2016 Nobel Prize.

Holista’s shares were last trading at $0.135, up 28.6% intra-day.

The all-natural, low-GI sugar is the newest addition to Holista’s low-GI suite of products.

The formula is being refined before testing at the world renowned GI Labs in Toronto for final validation.

As the product is made from natural ingredients, it is unlikely to face regulatory hurdles.

Holista expects to launch the product before June 2017.

High-GI foods are rapidly and easily converted to sugar, causing spikes in blood sugar levels that can lead to heart disease, diabetes and obesity over time.

Unlike other alternatives which can only be used in beverages, such as artificial sweeteners, Holista’s natural low-GI sugar can be melted, baked and caramelized for use in all cooking applications.

When consumed, it reduces the rate that glucose is digested throughout the body.

A 2012 study in the highly acclaimed scientific journal Nature suggested that sugar should be considered as toxic as other substances harmful to public health, such as alcohol or tobacco.

The authors urged government regulation to curb consumption, including taxes, advertisement restrictions, and even age requirements for purchase of sugary foods.





Register here to be notified of future HCT Company articles
View full HCT profile View Profile

Holista Colltech Ltd Timeline

Newswire
September 19 2017

Related Articles

the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
1507647205_biotech_517925923.jpg
October 11 2017
Last month the group revealed its Barocycler 2320EXTREME device had been selected as a finalist in the prestigious R&D 100 Awards for 2017.
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use